---
title: "Sarepta Therapeutics 将宣布 2025 年第四季度及全年财务结果"
description: "Sarepta Therapeutics, Inc. 将于 2026 年 2 月 25 日纳斯达克收盘后公布其 2025 年第四季度和全年财务业绩。随后将在东部时间下午 4:30 举行电话会议，讨论业绩情况，会议将通过公司网站进行现场直播。Sarepta 专注于罕见疾病的精准基因医学，特别是杜氏肌营养不良症，并在其网站上维护一个活跃的投资者关系部分以获取最新信息"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275618041.md"
published_at: "2026-02-11T14:02:32.000Z"
---

# Sarepta Therapeutics 将宣布 2025 年第四季度及全年财务结果

> Sarepta Therapeutics, Inc. 将于 2026 年 2 月 25 日纳斯达克收盘后公布其 2025 年第四季度和全年财务业绩。随后将在东部时间下午 4:30 举行电话会议，讨论业绩情况，会议将通过公司网站进行现场直播。Sarepta 专注于罕见疾病的精准基因医学，特别是杜氏肌营养不良症，并在其网站上维护一个活跃的投资者关系部分以获取最新信息

Sarepta Therapeutics Inc :

-   Sarepta Therapeutics 将于 2025 年第四季度及全年财务业绩发布。

### Related Stocks

- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [PBE.US - 动态生物技术与基因组 ETF - Invesco](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [SBIO.US - 医药突破 ETF - ALPS](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [IBB.US - 纳斯达克生物科技指数 ETF - iShares Nasdaq](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [IHE.US - 美国制药 ETF - iShares](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [ARKG.US - 基因改革 ETF - ARK](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [SRPU.US - Tradr 2X Long SRPT Daily ETF](https://longbridge.com/zh-CN/quote/SRPU.US.md)
- [VHT.US - 医疗业 ETF - Vanguard](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [FBT.US - 纽交所高增长板生物技术指数 ETF - First Trust](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [XBI.US - 标普生物技术 ETF - SPDR](https://longbridge.com/zh-CN/quote/XBI.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Immunic secures $400m fund to support commercial-stage development | Immunic has secured $400 million in funding, led by BVF Partners and joined by other institutional investors. The funds  | [Link](https://longbridge.com/zh-CN/news/276050237.md) |
| Merit Financial Group LLC Buys 1,397 Shares of Regeneron Pharmaceuticals, Inc. $REGN | Merit Financial Group LLC increased its stake in Regeneron Pharmaceuticals, Inc. by 302.4% in Q3, acquiring 1,397 additi | [Link](https://longbridge.com/zh-CN/news/276208818.md) |
| GSA Capital Partners LLP Increases Holdings in Edgewise Therapeutics, Inc. $EWTX | GSA Capital Partners LLP increased its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 315.2% in Q3, owning 113 | [Link](https://longbridge.com/zh-CN/news/276119404.md) |
| Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here? | Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here? | [Link](https://longbridge.com/zh-CN/news/276273938.md) |
| Unnatural Products, Novartis sign licensing agreement for cardiovascular program | Unnatural Products has entered a licensing agreement with Novartis to develop macrocyclic peptide-based therapies for ca | [Link](https://longbridge.com/zh-CN/news/276234107.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。